TMD Energy Announces $276.3M Revenue for 6M25, a 22.7% Decrease Compared to Last Year
Revenue Decline: Group revenue for 6M2025 was $276.3 million, a 22.7% decrease due to an 11.2% drop in bunkering volumes, attributed to challenges from the tariff crisis and global economic uncertainties.
Financial Performance: The company reported a net loss of $4.5 million for 6M2025, compared to a net income of $1.1 million in the same period the previous year, with rising operating costs and foreign exchange losses contributing to the downturn.
Operational Adjustments: The CEO highlighted efforts to optimize fleet deployment, expand high-margin ship-management contracts, and enhance cost efficiencies through digital tools and automation.
Future Strategies: The company is evaluating a prudent FX-hedging program and advancing its sustainability roadmap, focusing on transitioning to lower-carbon marine fuels and bioenergy.
Trade with 70% Backtested Accuracy
Analyst Views on TMDE
About TMDE
About the author

- FDA Approval: The U.S. Food and Drug Administration (FDA) lifted the clinical hold on GH Research Plc's (NASDAQ:GHRS) Investigational New Drug Application (IND) on Monday, enabling the company to proceed with its clinical trials, which is expected to accelerate product development and enhance market competitiveness.
- Positive Market Reaction: Following the announcement, GH Research's stock surged 34.5% to $17.80, reflecting investor optimism about the company's future potential and likely attracting more investor interest in its subsequent developments.
- Industry Impact: This FDA approval not only brings direct capital inflow to GH Research but may also encourage other biotech firms to expedite their clinical trial processes, thereby fostering innovation and growth across the industry.
- Increased Investor Confidence: With the clinical hold lifted, GH Research is poised to accelerate its product launch timeline in the coming months, further boosting investor confidence and enhancing the company's market position in the biopharmaceutical sector.

Nektar Therapeutics Stock Surge: Shares of Nektar Therapeutics rose 30.3% in pre-market trading after announcing the release date for top-line data from its Phase 2b REZOLVE-AD clinical trial on June 24, 2025.
Market Movements: Several stocks experienced significant pre-market movements, with iBio, Inc. gaining 55.8% and Upexi, Inc. dropping 62.3%, reflecting a mix of gains and losses across various companies.

Sequans Communications Investment: Shares of Sequans Communications rose 42.2% in pre-market trading after announcing a $384 million strategic investment for a bitcoin treasury initiative.
Market Movements: Several stocks experienced significant changes in pre-market trading, with OceanPal Inc. surging 86.1% and COMPASS Pathways PLC dropping 30.8%.

Partnership Announcement: TMD Energy Limited has signed a Memorandum of Agreement with Double Corporate Sdn Bhd to explore collaboration in sustainable bioenergy solutions for the EU and Asia markets, focusing on integrating alternative fuel energy sectors.
Company Backgrounds: Double Corporate specializes in converting waste into high-yield sustainable fuels using ISCC-EU-approved technology, while TMD Energy Limited provides marine fuel bunkering services across 19 ports in Malaysia.

Incyte Corporation's Stock Surge: Incyte shares rose 9.6% to $74.25 in pre-market trading following a collaboration announcement with QIAGEN to develop companion diagnostics for mutant CALR-expressing Myeloproliferative Neoplasms.
Pre-Market Trading Highlights: Several stocks experienced significant movements, including TMD Energy Limited (+203%), Regencell Bioscience Holdings (+169.6%), and Sarepta Therapeutics (-31.4%) after halting shipments and trials due to safety concerns.
Market Update: The trading week is nearing its end, but there are still significant stock market developments to follow on Friday.
Resource for Traders: TipRanks provides a list of the hottest market happenings and offers a guide to finding the best online brokers for trading.







